动脉瘤性蛛网膜下腔出血中改良尼莫地平给药方案的安全性
本研究为2016至2019年单中心回顾性队列,纳入175例接受尼莫地平的动脉瘤性蛛网膜下腔出血患者,49%(n=86)采用改良给药(30 mg每2小时)。改良给药与不良功能结局无关(逆概率加权RR 1.1,95%CI 0.8-1.4,P=0.65),作者认为改良给药耐受良好且可能不增加不良结局风险。
要点
- 改良尼莫地平给药(30 mg每2小时)与标准给药(60 mg每4小时)相比,不良功能结局无显著差异(RR 1.1,95%CI 0.8-1.4)。
- 女性、发生血管痉挛及需使用血管升压药的患者更常采用改良给药。
- 作者认为改良给药耐受良好,可能不增加不良功能结局风险,需前瞻性研究进一步评估。
核心结论
- 改良尼莫地平给药耐受良好,可能不增加不良功能结局风险;需前瞻性研究进一步评估尼莫地平给药与结局的关系。
研究设计与样本
- 回顾性队列研究,纳入2016至2019年单家学术转诊中心连续收治的动脉瘤性蛛网膜下腔出血患者。
- 纳入确诊动脉瘤病因且接受尼莫地平治疗者;排除入院24小时内死亡或撤除生命支持治疗者。
- 共纳入175例患者,平均(标准差)年龄57(13.2)岁,62%为女性,73%为白人;49%(n=86)接受改良尼莫地平给药(30 mg每2小时),其余接受标准给药(60 mg每4小时)。
- 采用单变量和多变量改良Poisson回归识别改良给药预测因素;采用逆概率加权和改良Poisson回归模型估计调整风险比(RR)。
- 不良结局定义为3个月时改良Rankin量表评分4-6分。
主要发现
- 女性更常采用改良给药(RR 2.08,95%CI 1.11-3.89,P=0.02)。
- 发生血管痉挛的患者更常采用改良给药(RR 3.47,95%CI 1.84-6.51,P<0.001)。
- 需使用血管升压药的患者更常采用改良给药(RR 1.73,95%CI 1.3-2.32,P<0.001)。
- 改良给药与不良功能结局无关(逆概率加权RR 1.1,95%CI 0.8-1.4,P=0.65)。
关键数值与推荐
- 改良尼莫地平给药定义为30 mg每2小时;标准给药定义为60 mg每4小时。
- 不良结局定义为3个月时改良Rankin量表评分4-6分。
- 改良给药与不良功能结局的逆概率加权RR为1.1(95%CI 0.8-1.4,P=0.65)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nimodipine improves outcomes in patients with aneurysmal subarachnoid hemorrhage (aSAH). However, the impact of alternative dosing strategies on outcome remains unclear. METHODS: We performed a retrospective cohort study of consecutive patients admitted with aSAH to an academic referral center from 2016 to 2019. Patients with a confirmed aneurysm cause who received nimodipine were included; patients who died or had withdrawal of life-sustaining treatment within 24 hours of admission were excluded. Univariable and multivariable modified Poisson regression models were used to identify predictors of using modified nimodipine dosing (30 mg every 2 hours) versus standard dosing (60 mg every 4 hours). Inverse probability weighted and modified Poisson regression models were used to estimate adjusted risk ratios (RRs) for outcome measures, with poor outcome defined as modified Rankin Scale score 4-6 at 3 months. RESULTS: We identified 175 patients with aSAH who met eligibility criteria (mean [SD] age = 57 [13.2] years, 62% female, 73% White); 49% (n = 86) received modified nimodipine dosing. A modified dose was used more frequently in women (RR 2.08, 95% confidence interval [CI] 1.11-3.89, P = 0.02), patients with vasospasm (RR 3.47, 95% CI 1.84-6.51, P < 0.001), and patients who required vasopressors (RR 1.73, 95% CI 1.3-2.32, P < 0.001). Modified dosing was not associated with poor functional outcome (inverse probability weighted RR 1.1, 95% CI 0.8-1.4, P = 0.65). CONCLUSIONS: Modified dosing of nimodipine is well tolerated and may not be associated with worse functional outcome. Prospective studies are needed to better assess the relationship between nimodipine dosing and outcomes in patients with aSAH.
引用
- Mahmoud L, Zullo AR, Blake C, et al. Safety of Modified Nimodipine Dosing in Aneurysmal Subarachnoid Hemorrhage. World Neurosurg. 2021. PMID: 34775086. doi:10.1016/j.wneu.2021.11.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。